After Pandemic, US FDA Commissioner Wants To Continue ‘Rolling Review’ Offered To COVID-19 Products

Stephen Hahn also said the expedited approval process could be even more efficient.

ReviewStamp_1200x675
The expedited assessment that COVID-19 product applications are receiving could become permanent FDA practice, along with some remote clinical trial monitoring practices. • Source: Shutterstock

The rolling application assessment that the US Food and Drug Administration is using for coronavirus therapeutics and vaccines may be among the pandemic-inspired regulatory changes that become standard practice.

FDA Commissioner Stephen Hahn said the agency’s approach to coronavirus therapeutics and vaccines, which included early engagement with sponsors and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Review Pathways

More from Pathways & Standards